Altium Capital Management LP Iveric Bio, Inc. Transaction History

Altium Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $1.12 Million - $1.47 Million	-60,000 Reduced 31.58%	130,000 $3.16 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $1.12 Million - $1.56 Million	65,000 Added 52.0%	190,000 $4.07 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $1.04 Million - $2.06 Million	-111,000 Reduced 47.03%	125,000 $2.24 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $1.13 Million - $1.57 Million	-93,101 Reduced 28.29%	236,000 $3.97 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $13,830 - $18,780	1,000 Added 0.3%	329,101 $5.5 Million
Q3 2021 Nov 17, 2021	SELL	$7.07 - $17.5 $7,070 - $17,500	-1,000 Reduced 0.3%	328,101 $5.33 Million
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $4.05 Million - $10 Million	-573,532 Reduced 63.54%	329,101 $5.99 Million
Q4 2020 Feb 16, 2021	BUY	$5.65 - $7.66 $5.1 Million - $6.91 Million	902,633 New	902,633 $6.24 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.